Method of treating pregnant cows and/or heifers

Abstract

The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.

1 . A method of preventing abortion in a pregnant cow, comprising administering a first vaccine to the cow prior to pregnancy wherein said first vaccine comprises a therapeutically effective amount of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type I and BVDV Type 2 and administering a second vaccine to the cow after the cow is pregnant, wherein said second vaccine comprises modified live IBR virus, modified live BVDV Type 1 derived from a Singer strain, modified live BVDV Type 2 derived from Strain 296, and  Haemophilus somnus.    
     
     
         2 . The method of  claim 1 , wherein the modified BVDV Singer strain is the one that is included in the BREED-BACK® FP5 vaccine. 
     
     
         3 . The method of  claim 1 , wherein the modified live BVDV Type 2 Strain 296 is the one that is included in the BREED-BACK® FP5 vaccine. 
     
     
         4 . The method of  claim 1 , wherein the modified live IBR is IBR Colorado 1 Strain. 
     
     
         5 . The method of  claim 4 , wherein the modified live IBR Colorado 1 Strain is the one that is included in the BREED-BACK® FP5 vaccine. 
     
     
         6 . The method of  claim 1 , wherein the second vaccine further comprises an immunologically active component effective for treatment or prophylaxis of an infection caused by a  Leptospira  bacterium. 
     
     
         7 . The method of  claim 6 , wherein the  Leptospira  bacterium is selected from the group consisting of:  Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae,  and  Leptospira pomona.    
     
     
         8 . The method of  claim 6 , wherein the  Leptospira  bacterium comprises  Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae,  and  Leptospira pomona.    
     
     
         9 . The method of  claim 1 , wherein the second vaccine is selected from the group consisting of BREED-BACK™ FP5-HS, EXPRESS™ 5-HS®, EXPRESS™ FP5-HS , BREED-BACK™ FP10, EXPRESS™ 10, BREEDBACK™ FP10-HS, EXPRESS FP10-HS®, and combinations thereof. 
     
     
         10 . The method of  claim 1 , further comprising the step of administering the second vaccine to the pregnant cow during the first, second or third trimester of pregnancy. 
     
     
         11 . The method of  claim 1 , wherein the second vaccine prevents the incidence of one or more clinical signs of an infection caused by a microbe selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof in a pregnant cow. 
     
     
         12 . The method of  claim 1 , wherein the second vaccine prevents the incidence of one or more clinical signs of an infection caused by a microbe selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof in a fetus of a pregnant cow. 
     
     
         13 . The method of  claim 1 , wherein the pregnant cow is a pregnant heifer. 
     
     
         14 . The method of  claim 1 , wherein the modified BVDV Singer strain is the one that is included in the BREED-BACK® FP5 vaccine. 
     
     
         15 . The method of  claim 1 , wherein the modified live BVDV Type 2 Strain 296 is the one that is included in the BREED-BACK® FP5 vaccine. 
     
     
         16 . The method of  claim 1 , wherein the modified live IBR is IBR Colorado 1 Strain. 
     
     
         17 . The method of  claim 16 , wherein the modified live IBR Colorado 1 Strain is the one that is included in the BREED-BACK® FP5 vaccine. 
     
     
         18 . The method of  claim 1 , wherein the first vaccine further comprises an immunologically active component effective for treatment or prophylaxis of an infection caused by a  Leptospira  bacterium. 
     
     
         19 . The method of  claim 18 , wherein the  Leptospira  bacterium is selected from the group consisting of:  Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae,  and  Leptospira pomona.